New report from 2020health - Cancer Commissioning: Making the reforms work for patients

A new report from the think-tank 2020health has expressed concern about the future of the provision of cancer care in the NHS and has warned that patients may suffer as a result.

The report concludes that the Government’s proposals do not go far enough to ensure improvements in cancer treatment will be made, and may even jeopardise progress made over the past decade.  There is growing concern that the Government's new commissioning structure will restrict integration and the work of cancer networks.

The report calls for greater patient involvement in the design and management of their care and concludes that the reforms should aim to build upon the success of the cancer networks.  It urges the Government to assure patients that, should cancer networks be replaced, services will be capable of delivering patient-focused improvements in cancer care.  The report also calls for greater mechanisms of accountability to improve the planning and management of cancer care.

The report can be viewed online here.

Page published: Fri 29 June 2012

It is supported by 8 companies:

  • Amgen
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Lilly
  • Novartis
  • Pfizer
  • Roche